Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Jan 2;2014(1):CD006569.
doi: 10.1002/14651858.CD006569.pub5.

Aripiprazole versus other atypical antipsychotics for schizophrenia

Priya Khanna  1 , Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel-Kluge, Hany George El-Sayeh, Stefan Leucht, Jun Xia
Affiliations
Meta-Analysis

Aripiprazole versus other atypical antipsychotics for schizophrenia

Priya Khanna et al. Cochrane Database Syst Rev. .

Abstract

Background: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first-line drug treatments for people with schizophrenia. In this review, we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics.

Objectives: To review the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses.

Search methods: We searched the Cochrane Schizophrenia Group Trials Register (November 2012), inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.

Selection criteria: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses.

Data collection and analysis: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study and used GRADE approach to rate quality of evidence.

Main results: We now have included 174 trials involving 17,244 participants. Aripiprazole was compared with clozapine, quetiapine, risperidone, ziprasidone and olanzapine. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with clozapine, there were no significant differences for global state (no clinically significant response, n = 2132, 29 RCTs, low quality evidence); mental state (BPRS, n = 426, 5 RCTs, very low quality evidence); or leaving the study early for any reason (n = 240, 3 RCTs, very low quality evidence). Quality of life score using the WHO-QOL-100 scale demonstrated significant difference, favouring aripiprazole (n = 132, 2 RCTs, RR 2.59 CI 1.43 to 3.74, very low quality evidence). General extrapyramidal symptoms (EPS) were no different between groups (n = 520, 8 RCTs,very low quality evidence). No study reported general functioning or service use.When compared with quetiapine, there were no significant differences for global state (n = 991, 12 RCTs, low quality evidence); mental state (PANSS positive symptoms, n = 583, 7 RCTs, very low quality evidence); leaving the study early for any reason (n = 168, 2 RCTs, very low quality evidence), or general EPS symptoms (n = 348, 4 RCTs, very low quality evidence). Results were significantly in favour of aripiprazole for quality of life (WHO-QOL-100 total score, n = 100, 1 RCT, MD 2.60 CI 1.31 to 3.89, very low quality evidence). No study reported general functioning or service use.When compared with risperidone, there were no significant differences for global state (n = 6381, 80 RCTs, low quality evidence); or leaving the study early for any reason (n = 1239, 12 RCTs, very low quality evidence). Data were significantly in favour of aripiprazole for improvement in mental state using the BPRS (n = 570, 5 RCTs, MD 1.33 CI 2.24 to 0.42, very low quality evidence); with higher adverse effects seen in participants receiving risperidone of general EPS symptoms (n = 2605, 31 RCTs, RR 0.39 CI 0.31 to 0.50, low quality evidence). No study reported general functioning, quality of life or service use.When compared with ziprasidone, there were no significant differences for global state (n = 442, 6 RCTs, very low quality evidence); mental state using the BPRS (n = 247, 1 RCT, very low quality evidence); or leaving the study early for any reason (n = 316, 2 RCTs, very low quality evidence). Weight gain was significantly greater in people receiving aripiprazole (n = 232, 3 RCTs, RR 4.01 CI 1.10 to 14.60, very low quality evidence). No study reported general functioning, quality of life or service use.When compared with olanzapine, there were no significant differences for global state (n = 1739, 11 RCTs, very low quality evidence); mental state using PANSS (n = 1500, 11 RCTs, very low quality evidence); or quality of life using the GQOLI-74 scale (n = 68, 1 RCT, very low quality of evidence). Significantly more people receiving aripiprazole left the study early due to any reason (n = 2331, 9 RCTs, RR 1.15 CI 1.05 to 1.25, low quality evidence) and significantly more people receiving olanzapine gained weight (n = 1538, 9 RCTs, RR 0.25 CI 0.15 to 0.43, very low quality evidence). None of the included studies provided outcome data for the comparisons of 'service use' or 'general functioning'.

Authors' conclusions: Information on all comparisons is of limited quality, is incomplete and problematic to apply clinically. The quality of the evidence is all low or very low. Aripiprazole is an antipsychotic drug with an important adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerge from ongoing larger, independent pragmatic trials.

PubMed Disclaimer

Conflict of interest statement

Tao Suo ‐ none known. Priya Khanna ‐ none known. Katja Komossa ‐ none known. Huai‐xing Ma ‐ none know.* Stefan Leucht ‐ has received honoraria for lectures from Abbvie, Astra Zeneca, BristolMyersSquibb, ICON, EliLilly, Janssen, Johnson & Johnson, Roche, SanofiAventis, Lundbeck and Pfizer; honoraria for consulting/advisory boards from Roche, EliLilly, Medavante, BristolMyersSquibb, Alkermes, Janssen, Johnson & Johnson and Lundbeck. EliLilly has provided medication for a study with Stefan Leucht as primary investigator. Christine Rummel ‐ has received lecture honoraria and travel grants to attend scientific meetings from AstraZenca, JanssenCilag, EliLilly and Pfizer. Heike Hunger ‐ none known. Sandra Schwarz ‐ none known. Hany George El‐Sayeh ‐ none known. Jun Xia ‐ none known.*

* no conflict of interest but authors work for a professional review company that received an incentive to complete this update (see also Sources of support).

Figures

1
1
Study flow diagram: original search
2
2
Study flow diagram: update 2011
3
3
Study flow diagram: update 2012
4
4
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
5
5
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
6
6
Funnel plot of comparison: 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, outcome: 1.1 Global state: 1. No clinically significant response (as defined by the original studies).
7
7
Funnel plot of comparison: 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, outcome: 2.1 Global state: 1.No clinically significant response (as defined by original studies).
8
8
Funnel plot of comparison: 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, outcome: 3.1 Global state: 1. No clinically significant response (as defined by the original studies).
9
9
Funnel plot of comparison: 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, outcome: 5.1 Global state: 1.No clinically significant response (as defined by the original studies).
1.1
1.1. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies).
1.2
1.2. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 2 Mental state: 1. Specific ‐ binary outcomes.
1.3
1.3. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 3 Mental state: 2. Average endpoint scores of various scales (short term, up to 12 weeks, high=poor).
1.4
1.4. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 4 Mental state: 3. Average endpoint scores of various scales (medium term, 12 to 26 weeks, high=poor).
1.6
1.6. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 6 Mental state: 5. Specific ‐ average endpoint positive score (PANSS, high=poor).
1.7
1.7. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 7 Mental state: 6. Specific ‐ average endpoint negative score (PANSS, high=poor).
1.8
1.8. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 8 Mental state: 7. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ).
1.9
1.9. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 9 Mental state: 8. Specific ‐ average total score decreased rate (PANSS, low=poor).
1.10
1.10. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 10 Mental state: 9. Specific ‐ average positive score decreased rate (PANSS, low=poor).
1.11
1.11. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 11 Leaving the study early.
1.12
1.12. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 12 Quality of life: 1a. Average scores (short term, up to 12 weeks, WHO‐QOL‐100, low=poor).
1.13
1.13. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 13 Quality of life: 1b. Average scores (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor).
1.14
1.14. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 14 Quality of life: 2. Average endpoint general quality of life score (GQOLI ‐ 74, low=poor).
1.15
1.15. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 15 Adverse effects: 1. At least one adverse effect.
1.16
1.16. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 16 Adverse effects: 2. Cardiac effects.
1.17
1.17. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 17 Adverse effects: 3. Central / peripheral nervous system.
1.18
1.18. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 18 Adverse effects: 4. Extrapyramidal effects.
1.19
1.19. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 19 Adverse effects: 6. Haematological.
1.20
1.20. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 20 Adverse effects: 5. Gastrointestinal.
1.21
1.21. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 21 Adverse effects: 7. Hormonal.
1.22
1.22. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 22 Adverse effects: 8a. Metabolic ‐ binary measures.
1.23
1.23. Analysis
Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 23 Adverse effects: 8b. Metabolic ‐ continuous measures (short term, up to 12 weeks, high=poor).
2.1
2.1. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by original studies).
2.2
2.2. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 2 Global state: 2a. Average endpoint total score (short term, up to 12 weeks, high=poor).
2.3
2.3. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 3 Global state: 2b. Average endpoint scale score (medium term, 12 to 24 weeks, high=poor).
2.4
2.4. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 4 Global state: 3. Average endpoint SI score (CGI, high=poor).
2.5
2.5. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 5 Mental state: 2a. Specific ‐ binary outcomes.
2.6
2.6. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 6 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor).
2.7
2.7. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 7 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor).
2.8
2.8. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 8 Mental state: 5. Specific ‐ average endpoint general pathological score (PANSS, high=poor ).
2.10
2.10. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 10 Leaving the study early.
2.11
2.11. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 11 Quality of life: Average score (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor).
2.12
2.12. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 12 Adverse effects:1. At least one adverse effect.
2.13
2.13. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 13 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks).
2.14
2.14. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 14 Adverse effects: 3. Central / peripheral nervous system.
2.15
2.15. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 15 Adverse effects: 4. Extrapyramidal symptoms ‐ various (short term, up to 12 weeks).
2.16
2.16. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 16 Adverse effects: 5. Gastrointestinal.
2.17
2.17. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 17 Adverse effects: 6. Haematological.
2.18
2.18. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 18 Adverse events: 7. Hormonal.
2.19
2.19. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 19 Adverse effects: 8a. Metabolic ‐ binary measures.
2.20
2.20. Analysis
Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 20 Adverse effects: 8b. Metabolic ‐ continuous measure.
3.1
3.1. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies).
3.2
3.2. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 2 Global state: 2. Average endpoint total score(short term, up to 12 weeks, CGI, high=poor).
3.3
3.3. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 3 Global state: 3. Average CGI subscale scores (short term, up to 12 weeks, high=poor).
3.5
3.5. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 5 Mental state: 1. Specific ‐ binary outcomes (short term, up to 12 weeks).
3.6
3.6. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 6 Mental state: 2. Average endpoint scale score.
3.7
3.7. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 7 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor).
3.8
3.8. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 8 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor).
3.9
3.9. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 9 Mental state: 5. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ).
3.10
3.10. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low=poor).
3.11
3.11. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high=poor).
3.12
3.12. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 12 Mental state: 8. General ‐ average total score (PANSS, high=poor).
3.14
3.14. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 14 Leaving the study early.
3.15
3.15. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 15 Adverse effects: 1. At least one adverse effect, non‐specific.
3.16
3.16. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks).
3.17
3.17. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 17 Adverse effects: 2b. Cardiac ‐ QTc change from baseline (in ms).
3.18
3.18. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 18 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks).
3.19
3.19. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 19 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ average change (ng/ml).
3.20
3.20. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 20 Adverse effects: 3b. Endocrine ‐ Prolactin‐associated.
3.21
3.21. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 21 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks).
3.22
3.22. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 22 Adverse effects: 4b. Extrapyramidal ‐ average score.
3.23
3.23. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 23 Adverse effects: 5. Gastrointestinal.
3.24
3.24. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 24 Adverse effects: 6. Haematological.
3.25
3.25. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 25 Adverse effects: 7a. Metabolic ‐ binary measures (short term, up to 12 weeks).
3.26
3.26. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 26 Adverse effects: 7b. Metabolic ‐ continuous measures (high=poor ).
3.27
3.27. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 27 Adverse effect : 7c. Metabolic ‐ continuous measures.
3.28
3.28. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 28 Adverse effect: 8. required additional drug combination.
3.29
3.29. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 29 Adverse effects: 9. TESS score (short term, up to 12 weeks, high=poor).
3.32
3.32. Analysis
Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 32 Cognitive functioning: 1. Specific ‐ average endpoint total score.
4.1
4.1. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies).
4.2
4.2. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 2 Global state: 2. Average endpoint CGI‐GI score (short term, up to 12 weeks, high=poor).
4.3
4.3. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 3 Global state: 3. Average change score (CGI‐S, decline=good).
4.4
4.4. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 4 Mental state: 1. Average endpoint total score (short term, up to 12 weeks, high=poor).
4.5
4.5. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 5 Mental state: 2. Specific ‐ binary outcomes (up to 12 weeks ‐ short term).
4.6
4.6. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 6 Mental state: 3. Specific ‐ average endpoint PANSS subscale scores (short term, high=poor).
4.8
4.8. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 8 Leaving the study early.
4.9
4.9. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 9 Adverse effects: 1. At least one adverse effect, non‐specific.
4.10
4.10. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 10 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks).
4.11
4.11. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 11 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks).
4.12
4.12. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 12 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks).
4.13
4.13. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 13 Adverse effects: 5. Gastrointestinal (short term, up to 12 weeks).
4.14
4.14. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 14 Adverse effects: 6. Haematological.
4.15
4.15. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 15 Adverse effects: 7. Hormonal.
4.16
4.16. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 16 Adverse effects: 8a. Metabolic ‐ binary measures.
4.17
4.17. Analysis
Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 17 Adverse effects: 8b. Metabolic ‐ continuous measures.
5.1
5.1. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by the original studies).
5.2
5.2. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 2 Global state: 2. Not responded (decline in PANSS of 30% or more).
5.3
5.3. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 3 Global state: 3. Remission not achieved (as defined in the study).
5.4
5.4. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 4 Global state: 4. Average endpoint EI score (CGI, high=poor).
5.5
5.5. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 5 Global state: 5. Average endpoint CGI score decreased rate (short term, low=poor).
5.6
5.6. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 6 Global state: 6. Average change score (CGI‐S, decline=best).
5.7
5.7. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 7 Global state: 7. Improvement (CGI‐I, high=poor).
5.8
5.8. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 8 Mental state: 1. Average endpoint scale score (PANSS, high=poor).
5.9
5.9. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 9 Mental state: 2. Average endpoint scale score (SANS, high=poor).
5.11
5.11. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 11 Mental state: 4. Specific ‐ average endpoint positive score (PANSS, high=poor).
5.12
5.12. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 12 Mental state: 5. Specific ‐ average endpoint negative subscale score (PANSS, high=poor).
5.13
5.13. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 13 Mental state: 6. Specific ‐ average endpoint general pathological score (PANSS, high=poor ).
5.14
5.14. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 14 Mental state: 7. Specific ‐ binary outcomes.
5.16
5.16. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 16 Adverse effects: 1. At least one adverse effect.
5.17
5.17. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 17 Adverse effects: 2. Cardiac effects.
5.18
5.18. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cardiac ‐ QTc change from baseline (in ms).
5.19
5.19. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Central / peripheral nervous system.
5.20
5.20. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 20 Adverse effects: 4. Endocrine ‐ Prolactin ‐ average increase.
5.21
5.21. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 21 Adverse effects: 5. Extrapyramidal ‐ various.
5.22
5.22. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 22 Adverse effects: 6. Gastrointestinal.
5.23
5.23. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 23 Adverse effects: 7. Hormonal.
5.24
5.24. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 24 Adverse effects: 8a. Metabolic ‐ binary measures.
5.25
5.25. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 25 Adverse effects: 8b. Metabolic ‐ continuous measures (high=poor).
5.27
5.27. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 27 Leaving the study early.
5.28
5.28. Analysis
Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 28 Quality of life: 1. Average endpoint general quality of life score (GQOLI‐74, low=poor).
6.1
6.1. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 1 Global state: Average improvement (BPRS, high=good).
6.2
6.2. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 2 Mental state: Specific ‐ binary outcomes.
6.3
6.3. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 3 Leaving the study early.
6.4
6.4. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 4 Adverse effects: 1. Central nervous system.
6.5
6.5. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 5 Adverse effects: 2. Endocrine ‐ Prolactin ‐ average increase.
6.6
6.6. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 6 Adverse effects: 3a. Extrapyramidal ‐ various.
6.7
6.7. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 7 Adverse effects: 3b. Extrapyramidal ‐ average score.
6.8
6.8. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 8 Adverse effects: 4. Gastrointestinal.
6.9
6.9. Analysis
Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 9 Adverse effects: 5. Metabolic ‐ continuous measures.
7.1
7.1. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 1 Global state: 1. No change (as defined in the study, measured by IAQ).
7.2
7.2. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 2 Global state: 2. Change in sexual dysfunction (ASEX).
7.3
7.3. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: Specific ‐ binary outcomes.
7.4
7.4. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 4 Preference: Study medication worse than or equal to previous medication.
7.5
7.5. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 5 Quality of life: 1. Unsatisfactory response on health dimension scale.
7.6
7.6. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 6 Quality of life: 3. Average change score (QLS, high=better)).
7.7
7.7. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 7 Quality of life: 2. Average score (EQ‐5D utility score, high=better).
7.8
7.8. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 8 Quality of life: 4a. Weight related ‐ No meaningful change (IWQOL‐Lite).
7.9
7.9. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 9 Quality of life: 4b. Weight related ‐ average score (IWQOL‐Lite, high=better).
7.10
7.10. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 10 Leaving the study early.
7.11
7.11. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 11 Adverse effects: 1. At least one adverse effect.
7.12
7.12. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 12 Adverse effects: 2. Central nervous system.
7.13
7.13. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 13 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ increase in level.
7.14
7.14. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 14 Adverse effects: 3b. Endocrine ‐ Prolactin ‐ Change in level.
7.15
7.15. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 15 Adverse effects: 4. Extrapyramidal ‐ akathisia.
7.16
7.16. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 16 Adverse effects: 5. Gastrointestinal.
7.17
7.17. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 17 Adverse effects: 6a. Metabolic‐ binary measures.
7.18
7.18. Analysis
Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 18 Adverse effects: 6b. Metabolic ‐ continuous measures.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

An 2008 {published data only}
    1. Ai C‐Q, Chen S‐M. Comparison study in the treatment of schizophrenia between aripiprazole and clozapine [阿立哌唑与氯氮平治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(1):53‐4.
Bai 2007 {published data only}
    1. Bai S‐X, Yan L, Ding X‐M. Comparative study on the efficacy of aripiprazole and clozapine in treatment of schizophrenia [阿立哌唑和氯氮平对首发精神分裂症患者疗效及对心电图影响的对照研究]. 中国临床实用医学 2007;1(4):39‐40.
Bai 2009 {published data only}
    1. 白剑文. ziprasidone and aripiprazole in the treatment of schizophrenia] Google Translate [齐拉西酮与阿立哌唑治疗精神分裂症对照研究 []. 青岛医药卫生 2009; Vol. 41, issue 3:199‐200.
Ban 2008 {published data only}
    1. Ban N, Cui J‐B. Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia [阿立哌唑与奎硫平治疗精神分裂症的疗效分析]. Occupation and Health [职业与健康] 2008;24(3):292‐3.
Chan 2007 {published data only}
    1. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. Journal of Clinical Psychiatry 2007;68(1):29‐36. - PubMed
    1. Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG, Cheng MY, et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. Journal of the European College of Neuropsychopharmacology 2005;14(Suppl 3):S497.
Chang 2007 {published data only}
    1. Chang S. A control study of aripiprazole vs. risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(4):335‐6.
Chen 2006 {published data only}
    1. Chen H, Liu Z, Gong J, Chen H, Hu D, Wang D. Comparative study of therapeutic effects between aripiprazole and risperidone on schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Shanghai Medical and Pharmaceutical Journal [上海医药] 2006;27(9):404‐6.
Chen 2007a {published data only}
    1. 陈飞, 王红艳, 李德咏, 周保卫, 程夫英. Aripiprazole, quetiapine treatment of female episode schizophrenia [阿立哌唑、喹硫平治疗女性首发精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2007; Vol. 20, issue 6:381‐3.
Chen 2008a {published data only}
    1. 陈震雷, 黄艳. Aripiprazole and risperidone in the treatment of female schizophrenia [阿立哌唑与利培酮治疗女性精神分裂症的对照研究]. Modern Research of Integrated Chinese and Western Medicine [现代中西医结合杂志] 2008;17(35):5454‐5.
Chen 2009 {published data only}
    1. 陈红英, 张郦, 付迎春, 季海峰, 费玥, 黄雅南. Aripiprazole and quetiapine in the treatment of schizophrenia] Google Translate [阿立哌唑和喹硫平治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2009;22(1):53‐4.
Chen 2009a {published data only}
    1. 陈远岭, 黄文武, 叶鑫武. Comparative study between aripiprazole and olanzapine in the treatment of agitated schizophrenia [阿立哌唑治疗伴激越的精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;19(4):261‐2.
Chen 2010 {published data only}
    1. 陈平勋, 罗建慈, 刘桃芳. Aripiprazole and risperidone in the treatment of schizophrenia in the clinical control study] Google Translate [阿立哌唑与利培酮治疗精神分裂症的临床对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010; Vol. 22, issue 17:2249‐50.
Chen 2010a {published data only}
    1. 陈恩民. Aripiprazole and risperidone in the treatment of schizophrenia starting] Google Translate [阿立哌唑与利培酮治疗首发精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(17):2180‐4.
Cheng 2009 {published data only}
    1. 程平, 王天龙, 陈红光, 唐鹏, 周桂明. Ziprasidone and Aripiprazole in the treatment of schizophrenia with predominantly negative symptoms [齐拉西酮与阿立呱唑治疗以阴性症状为主的精神分裂症对照研究]. Journal of the Xianning Medical College [新乡医学院学报] 2009;23(2):106‐8.
CuiMeng 2008 {published data only}
    1. CuiMeng. Compare the aripiprazole with risperidone to treat schizophrenia disease [利培酮与阿立哌唑治疗120例精神分裂症效果对比分析]. Journal of the Mudanjiang Medical College 2008;29(3):20‐2.
Dai 2005 {published data only}
    1. Dai J‐P, Zhao Z‐H, Liu G‐X. Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia [阿立哌唑與奎硫平治療精神分裂癥療效和安全性比較]. Chinese Journal of Behavioral Medical Science [中国行为医学科学] 2005;14(8):712‐4.
Dai 2006 {published data only}
    1. Dai T. A comparison of schizophrenia with aripiprazole and risperidone [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Journal of the Datong Medical College 2006;26(1):14‐5.
Deng 2008 {published data only}
    1. 邓克文, 张永福, 张海风. Effects were compared aripiprazole in the treatment of elderly schizophrenia [阿立哌唑治疗老年精神分裂症的疗效对比观察]. Sichuan Mental Health [四川精神卫生] 2008;21(1):28‐9.
Deng 2008a {published data only}
    1. 邓华, 赵梅秀. Control study of domestic aripiprazole and risperidone in the treatment of schizophrenia [国产阿立哌唑与利培酮治疗精神分裂症的对照研究]. Journal of the Youjiang Medical College for Nationalities 2008;5:755‐6.
Ding 2007 {published data only}
    1. 丁永红, 周庆海, 邓金英. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. 中国现代医生 2007; Vol. 45, issue 17:87.
Du 2006 {published data only}
    1. Du B, Zhao S‐M, Tian G‐Q. Study on effects of aripiprazole on serum prolactin level and body weight [阿立哌唑对精神分裂症患者血清催乳素及体重的影响]. Chinese General Practice [中国全科医学] 2006;9(13):1065‐6.
Fan 2005 {published data only}
    1. Fan W‐L, Yu C‐M, Wen J‐S. Efficacy analysis of aripiprazole and clozapine in the treatment of schizophrenia. Journal of North Sichuan Medical College 2005;20(4):377‐9.
Fan 2010 {published data only}
    1. 范文澜, 余成民, 李正发. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症的对照研究 []. 西部医学 2010; Vol. 22, issue 6:1051‐2.
Feng 2006 {published data only}
    1. Feng Y, Yan X, Zhao Z. The clinical study on aripiprazole and risperidone in trea tment of first‐onset schizophrenia [阿立哌唑与利培酮治疗首发精神分裂症患者疗效的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(4):418‐9.
Fleischhacker 2008 {published data only}
    1. BMS. A multicenter, double‐blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Clinical Study Report CN138003 2005.
Fu 2009 {published data only}
    1. 傅深省, 朱菇苓, 郭文勇, 刘一呜, 乔胜宇. Comparative study of Aripiprazole with risperidone in the treatment of adolescent patients with first episode schizophrenia [阿立哌唑与利培酮治疗青少年首发精神分裂症对照研究]. Journal of Qiqihar Medical College [齐齐哈尔医学院学报] 2009;30(8):905‐6.
Ge 2009 {published data only}
    1. 袁纯玲. Quetiapine and aripiprazole in the treatment control study of first‐episode schizophrenia] Google Translate [喹硫平和阿立哌唑治疗首发精神分裂症对照研究]. 中国现代药物应用 2009; Vol. 2, issue 3:71.
Ge 2010 {published data only}
    1. 葛淑君, 王春艳, 朱丹. Aripiprazole and quetiapine in the treatment of women with schizophrenia] Google Translate [阿立哌唑与喹硫平治疗女性精神分裂症对照研究 []. Chinese General Practice [中国全科医学] 2010;13(5):46‐7.
Guo 2006 {published data only}
    1. Guo X‐F, Chen J‐D, Zhao J‐P. A randomized and double‐blind controlled clinical trial of aripiprazole in the treatment of schizophrenia [阿立哌唑治療精神分裂癥的隨機雙盲對照試驗]. Journal of Clinical Research 2006;23(5):716‐8.
Han 2005 {published data only}
    1. Han P, Zhang Y‐H, Zhang C‐Z. Quality of life in schizophrenics treated with aripiprazole or clozapine. Chinese Journal of Rehabilitation Theory and Practice 2006;12(12):995‐6.
    1. Han P, Zhang Y‐H, Zhang Y‐Q. A controlled study of schizophrenia treated with aripiprazole and clozapine. Chinese Journal of Rehabilitation Theory and Practice [中国康复理论与实践] 2005;11(10):853‐4.
Han 2007 {published data only}
    1. Han Y, Li Y, Ren C. Clinical effect of the domestic olanzapine and aripiprazole in the treatment of schizophrenia [国产奥氮平与阿立哌唑治疗精神分裂症的临床研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2007;15(1):28‐9.
Han 2007a {published data only}
    1. 韩雪峰, 范连梅. Aripiprazole and risperidone in the treatment of clinical studies of schizophrenia [阿立哌唑与维思通治疗精神分裂症的临床研究]. Journal of Practical Medical Techniques [实用医技杂志] 2007; Vol. 14, issue 31:4298‐9.
Hu 2010 {published data only}
    1. 胡亚湘, 崔炳喜, 于浚玫, 崔鹏, 秦颖. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Tianjin Pharmacy 2010;22(1):41‐3.
Huang 2009 {published data only}
    1. 黄河亮, 王桂香. A comparative study in earlier schizophrenic patients treated with aripiprazole and risperidone [阿立哌唑与利培酮治疗早期精神分裂症的疗效和安全性研究]. 中国医药指南 2009;7(16):15‐7.
Ji 2007 {published data only}
    1. Ji D‐C, Yu C‐X, Sun Y‐J, Huang M, Huang Q. A study of aripiprazole and risperidone in treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007;17(4):261‐2.
Jiang 2009 {published data only}
    1. Jiang G, Luo J. Aripiprazole and clozapine in treatment refractory schizophrenia randomized controlled study] Google Translate. Chongqing Medical Journal 2009;38(1):87‐8.
Jie 2008 {published data only}
    1. Jie R, Wang G. Aripiprazole and clozapine treatment of schizophrenia with predominantly negative symptoms. Sichuan Mental Health 2008;21(2):107‐9.
Kane 2009 {published data only}
    1. Ascher‐Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al. Cost‐effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion 2011;27(1):115‐22. - PubMed
    1. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Biological Psychiatry 2008;63(7 Suppl):289S. - PubMed
    1. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. 2008. - PubMed
    1. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, et al. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry 2009;70(4):572‐81. [MEDLINE: ] - PubMed
    1. Osuntokun O, Kane JM, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2008;11(Suppl 1):153. - PubMed
Kern 2006 {published data only}
    1. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open‐label comparison with olanzapine. Psychopharmacology 2006;187(3):312‐20. - PubMed
Kerwin 2007 {published data only}
    1. Beuzen JN, L'Italien G, Hanssens L, Marcus RN, McQuade RD, Carson WH. Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin 2007;33(2):421‐2.
    1. Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry 2008;69(5):741‐8. [MEDLINE: ] - PubMed
    1. Hanssens L, L'Italien G, Marcus RN, McQuade RD, Carson WH, Beuzen JN. Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin 2007;33(2):432.
    1. Hanssens L, L’ Italien G, McQuade R, Iwamoto T, Pans M. Evaluation of quality of life in community‐treated schizophrenic patients: a naturalistic, open‐label study comparing aripiprazole to standard‐of‐care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry 2006;21(Suppl 1):S99.
    1. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry 2007;22(7):433‐43. [MEDLINE: ] - PubMed
Kinon 2004 {published data only}
    1. Eli Lilly, Company. Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry 2004.
    1. Kinon BJ, Stauffer VL, Kollack‐Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(6):601‐7. [MEDLINE: ] - PubMed
    1. Stauffer V, Kinon B, Kollack‐Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. - PubMed
Kuang 2006 {published data only}
    1. Kuang L‐P. A controlled study on quality of life of schizophrenia treated with aripiprazole and clozapine [阿立哌唑与氯氮平对精神分裂症患者生活质量影响的对照研究]. Medical Journal of Chinese Civil Administration[中国民康医学] 2006;18(9):690‐1.
    1. Kuang L‐P, Xue Z‐M. A controlled study on compliance of schizophrenia treated with aripirazole and clozapine [阿立哌唑与氯氮平对精神分裂症患者治疗依从性的对照研究]. Chinese Journal of Clinical Psychology[中国临床心理学杂志] 2006;14(4):426‐7.
Li 2006 {published data only}
    1. Li G‐R, Lu P‐X, Li Y‐D. A comparative study of aripiprazole and risperidone in the treatment of first‐episode schizophrenia [阿立哌唑与利培酮治疗首发精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2006;19(3):196‐7.
Li 2006a {published data only}
    1. Li L‐X, Lian H‐T. A comparative study of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2006; Vol. 18, issue 9:723‐4.
Li 2007 {published data only}
    1. Li M, Wu N, Li Y‐F. Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology 2007;15(10):956‐7.[MEDLINE:].
Li 2007a {published data only}
    1. Li Q, Li G, Li G. Effects of aripiprazole and clozapine on life quality of schizophrenics. Journal of Clinical Psychosomatic Diseases 2007;13(5):404‐6.[MEDLINE: ].
    1. 陈玲, 王俊超. Aripiprazole and clozapine on quality of life of patients with schizophrenia] Google Translate [阿立哌唑与氯氮平对精神分裂症患者生活质量的影响]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(15):1939‐41.
Li 2007b {published data only}
    1. 李美花, 吕伟, 邢秀娟. Aripiprazole and quetiapine in the treatment of schizophrenia [阿立哌唑和喹硫平治疗精神分裂症的对照研究]. 中国医师进修杂志 2007;30(11A):49‐50.
Li 2007c {published data only}
    1. Li H. Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia [阿立哌唑和齐拉西酮治疗精神分裂症的临床比较]. International Medicine and Health Guidance News [国际医药卫生导报] 2007;13(11):77‐9.
Li 2007d {published data only}
    1. Li C, Deng L, Feng W. Control studies of domestic aripiprazole vs. risperidone in the treatment of schizophrenia [国产阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(2):100‐2.
Li 2009 {published data only}
    1. 李晓英, 刘琦. Aripiprazole and clozapine treatment of schizophrenia control study of efficacy and safety] Google Translate [阿立哌唑与氯氮平治疗精神分裂症疗效与安全性对照研究]. 甘肃科技 2009;25(16):135‐41.
Li 2009a {published data only}
    1. 李代秀, 陈波, 丁静华. Aripiprazole and risperidone in the treatment of schizophrenia compared] Google Translate [阿立哌唑与利培酮治疗精神分裂症的疗效对比]. Baotou Medical Journal 2009; Vol. 33, issue 1:13‐4.
Li 2009b {published data only}
    1. 李晓华. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症的对照研究]. 中国实用医药 2009;4(18):166‐7.
Lian 2008 {published data only}
    1. 连树奎, 林德颖. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. 中国现代医生 2008; Vol. 46, issue 14:91‐2.
Liang 2008 {published data only}
    1. 梁佳, 陶建青, 康红. Compliance control study of aripiprazole and risperidone in the treatment of patients with schizophrenia [阿立哌唑与利培酮治疗精神分裂症患者依从性的对照研究]. Guangxi Medical Journal 2008; Vol. 30, issue 1:30‐1.
Liu 2006 {published data only}
    1. Liu S, Ren C, Song X. Comparative study between aripiprazole and clozapine in the treatment of first‐episode schizophrenia [阿立哌唑与氯氮平治疗首发精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006; Vol. 14, issue 6:658‐9.
Liu 2006a {published data only}
    1. Liu W, Yang K, Zuo X. A control study on aripiprazole and risperidone in the treatment of schizophrenia [阿立派唑与利培酮治疗精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(4):420‐1.
Liu 2007 {published data only}
    1. Liu B. A control study on aripiprazole vs. clozapine in the treatment of refractory schizophrenia [阿立哌唑与氯氮平治疗难治性精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(6):500‐1, 507.
Liu 2008 {published data only}
    1. Liu J, Ren J, Wang Y. Aripiprazole and clozapine treatment episode schizophrenia. 中国实用医药 2008; Vol. 3, issue 4:55‐7.
Liu 2008a {published data only}
    1. Liu W, Zhang X. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms [齐拉西酮与阿立哌唑治疗以阴性症状为主的精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2008; Vol. 16, issue 2:124‐5.
Liu 2008b {published data only}
    1. 刘从敏. Aripiprazole for schizophrenia patients with psychiatric symptoms and quality of life impact [阿立哌唑对精神分裂症患者的精神症状及生活质量的影响研究]. 中国医药导报 2008;5(19):110‐1.
Liu 2008c {published data only}
    1. 刘伟锋, 张卫敏. Aripiprazole and risperidone in the treatment of refractory schizophrenia Efficacy [阿立哌唑与利培酮治疗难治性精神分裂症疗效观察]. Medical Journal of Chinese People's Health [中国民康医学] 2008; Vol. 20, issue 3:224‐5.
Liu 2008d {published data only}
    1. 刘峥嵘, 郗晓明, 李丽颖. Aripiprazole and risperidone in the treatment episode schizophrenia [阿立哌唑和利培酮治疗首发精神分裂症对照研究]. Chinese Medical Journal of Metallurgical Industry [中国冶金工业医学杂志] 2008;25(3):276‐7.
Liu 2009 {published data only}
    1. 刘娟, 李洪英. Aripiprazole and olanzapine schizophrenia] Google Translate [阿立哌唑与奥氮平治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2009; Vol. 22, issue 5:339‐40.
Liu 2009a {published data only}
    1. 刘志东. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Medical Theory and Practice 2009; Vol. 22, issue 9:1072‐3.
Liu 2009b {published data only}
    1. 刘昊, 朱怀轩, 赵勤, 谭权. Aripiprazole and quetiapine in the treatment of schizophrenia] Google Translate [阿立哌唑与喹硫平治疗精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2009;22(1):42‐3.
Liu 2010 {published data only}
    1. 刘卉兰, 张香云, 栗克清, 桑文华, 张彦恒, 田桂平, et al. Clozapine, risperidone and aripiprazole adverse drug reactions cost ‐ effectiveness analysis] Google Translate [氯氮平、利培酮和阿立哌唑药物不良反应成本‐效果分析]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2010;18(6):646‐8.
Li X 2007 {published data only}
    1. 李曦, 王萍, 娄涛. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(12):1064, 1067.
Lou 2007 {published data only}
    1. Lou T, Li N, Wu X‐Y, Wang C‐S. Effect of aripiprazole on late‐onset schizophrenia and cognitive function [阿立哌唑治疗晚发精神分裂症的疗效观察及其对认知功能的影响]. Chinese New Drugs Journal [中国新药杂志] 2007;16(20):1709‐12.
Luo 2008 {published data only}
    1. Luo X, An B‐F. Comparison of quetiapine and aripiprazole in the treatment of first episode schizophrenia [奎硫平与阿立哌唑治疗首发精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(3):191‐2.
Luo 2009 {published data only}
    1. 罗来兴. Aripiprazole and risperidone in the treatment of schizophrenia efficacy analysis [阿立哌唑与利培酮治疗精神分裂症疗效分析]. 当代医学 2009;15(170):101‐2.
Lv 2007 {published data only}
    1. Lv T‐H, Jin C‐X. A comparative study on aripiprazole and risperidone in the treatment of schizophrenic patients [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(5):181‐2.
Ma 2009 {published data only}
    1. 麻显娇, 卢喜金, 邹晓华. Aripiprazole and olanzapine in negative symptoms in schizophrenia] Google Translate [阿立哌唑与奥氮平治疗以阴性症状为主的精神分裂症对照研究]. China Pharmaceuticals [中國藥業] 2009;18(23):59‐60.
Ma 2009a {published data only}
    1. 马忠智, 陈春武. Efficacy of aripiprazole and risperidone in the treatment of early schizophrenia [阿立哌唑与利培酮治疗早期精神分裂症的疗效观察]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009;17(6):643‐4.
Mai 2005 {published data only}
    1. Mai G‐Y, Cai G‐H, Huang J‐M. Comparative study on the effect of aripiprazole and risperidone on schizophrenia. Chinese Journal of Rehabilitation [中國康復] 2005;20(3):184‐5.
Mao 2010 {published data only}
    1. 毛星, 刘洪秋, 陈玉辉. Olanzapine and aripiprazole in the treatment of refractory schizophrenia control study of 70 cases] Google Translate [奥氮平与阿立哌唑治疗难治性精神分裂症70例的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(11):1365‐6.
McQuade 2004 {published data only}
    1. Abou Gharbia N, McQuade R, Jody D, Kujawa M, Carson W, Iwamoto T, et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10‐13; Florence, Italy. 2004.
    1. Blonde L, Ray S, Corey‐Lisle PK, Cislo PR, L'Italien G. The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S275.
    1. Jody D, McQuade RD, Kujawa M, Carson W, Iwamoto T, Archibald D, et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research 2004;67(1):187.
    1. McQuade RD, Jody D, Kujawa MJ, Carson WH, Iwamoto T, Archibald DG, et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003.
    1. McQuade RD, Kujawa M, Saha AR, Ingenito GG, Ali MW, Luo X, et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research 2003;60(1):295.
Mu 2008 {published data only}
    1. 穆德军, 王龙锦, 王巍. Domestic aripiprazole and risperidone in the treatment of female schizophrenia [国产阿立哌唑和利培酮治疗女性精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(23):2781, 2783.
Mu 2010 {published data only}
    1. 沐志强, 杨顺英, 李弼. Aripiprazole and risperidone in the treatment of schizophrenia compared] Google Translate [阿立哌唑与利培酮治疗精神分裂症的疗效对比]. Medical Information 2010;3:641‐3.
Pan 2007 {published data only}
    1. Pan G. A controlled study of aripiprazole and risperdal in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2007;15(4):363‐4.
Peng 2007 {published data only}
    1. Peng X, Huang Y, Liu X‐Y. A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia [阿立哌唑与奎硫平治疗首发精神分裂症对照分析]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007;17(5):329‐30.
Peng 2007a {published data only}
    1. Peng Z‐Y, Mao W‐L. Comparative study between aripiprazole and clozapine in the treatment of schizophrenia [阿立哌唑与氯氮平治疗精神分裂症对照研究]. Journal of the Gannan Medical College [赣南医学院学报] 2007;27(2):237‐8.
Potkin 2003 {published data only}
    1. Potkin SG, Kujawa M, Carson WH, Saha AR, Ali M, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research 2003;60:300. - PubMed
    1. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003;60(7):681‐90. - PubMed
Pu 2007 {published data only}
    1. Pu S‐B, Liang J‐X, Zhang W‐S. The comparison of blood prolactin and body index in the female patients with psychosis treated by aripiprazole and risperidone [阿立派唑与利培酮对女性患者血清催乳素及体型指数影响的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007; Vol. 19, issue 5:163‐4, 7.
Qian 2009 {published data only}
    1. 钱文胜. Aripiprazole and olanzapine treatment of female control study of patients with schizophrenia] Google Translate [阿立哌唑与奥氮平对女性精神分裂症患者治疗的对照研究]. 兵团医学 2009; Vol. 1, issue 19:28‐9.
Qin 2008 {published data only}
    1. 秦爱玲, 李敏, 胥爱萍. Aripiprazole and risperidone in the treatment of chronic schizophrenia [阿立哌唑与利培酮治疗慢性精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(4):284, 300.
Qu 2009 {published data only}
    1. 曲万仁. The comparison for effect of treating schizophrenia with aripiprazole and risperidone [阿立哌唑与利培酮治疗120例精神分裂症对比]. Chinese Journal of Ethnomedicine and Ethnopharmacy 2009; Vol. 6:33.
Shan 2008 {published data only}
    1. Shan H. A controlled study of aripiprazole vs. risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2008;14(2):119‐20, 133.
Shuai 2008 {published data only}
    1. Shuai H. Evaluating the effect and safety of aripirazole and risperidone [阿立哌唑与利培酮疗效及安全性评价]. 中国现代医药杂志 2008;10(2):35‐7.
Song 2008 {published data only}
    1. 宋艳萍. Comparative analysis of aripiprazole and risperidone in the treatment of female schizophrenia [阿立哌唑与利培酮治疗女性精神分裂症的对照分析]. Sichuan Mental Health [四川精神卫生] 2008; Vol. 21, issue 1:34‐5.
Song 2009 {published data only}
    1. 宋长惠. Aripiprazole Comparative Study of Risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑 利培酮治疗精神分裂症对比研究]. Journal of Medical Forum [医药论坛杂志] 2009;30(19):67‐8.
Song 2010 {published data only}
    1. 宋芳. Olanzapine and aripiprazole in the treatment of schizophrenia] Google Translate [奥氮平与阿立哌唑治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(8):970, 986.
Su 2007 {published data only}
    1. 栗小红. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2007; Vol. 20, issue 5:313‐4.
Su 2008 {published data only}
    1. Su Q, Huang H‐R, Gao A‐Q, Huang D. A comparative study of olanzapine and aripiprazole in treatment of schizophrenia [奥氮平与阿立哌唑治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(6):409‐10.
Sun 2006 {published data only}
    1. Sun Q, Guo H, Liu Y. Effect of aripiprazole on coginiton function in patients with schizophrenic [奥派对精神分裂症患者认知功能的影响]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(4):424‐6.
Sun 2009 {published data only}
    1. 孙东, 江琴普, 李建锋, 李薇, 杨老虎. Control study on aripiprazole in the treatment of first‐episode schizophrenia [阿力哌唑治疗首发精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009; Vol. 17, issue 7:774‐6.
Sun 2009a {published data only}
    1. 孙德生, 尹焕新. Quetiapine and aripiprazole in the treatment of schizophrenia] Google Translate [奎硫平与阿立哌唑治疗精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009;17(12):1416‐7.
Tandon 2006 {published data only}
    1. Riera L, Hu R, Stock E, Nyilas M, Torbeyns A, Borian F, et al. Broad effectiveness trial with aripiprazole. Schizophrenia Research 2004;67(1):157. - PubMed
    1. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research 2006;84(1):77‐89. - PubMed
Tang 2006 {published data only}
    1. Tang Q, Lai G, Zhang J. Aripiprazole and risperidone in the treatment of female schizophrenics [阿立哌唑和利培酮治疗女性精神分裂症的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學] 2006;18(1):30‐2.
Tang 2007 {published data only}
    1. Tang C‐G, Wang R‐C. Comparison of efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮的疗效和安全性比较]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(17):727‐8.
Tang 2010 {published data only}
    1. Tang Q. Aripiprazole and risperidone in the treatment efficacy of first‐episode schizophrenia] Google Translate [阿立哌唑和利培酮治疗首发精神分裂症的疗效观察]. Chinese Journal of Pharmaco Epidemiology [药物流行病学杂志] 2010; Vol. 19, issue 1:13‐4, 20.
Tang 2010a {published data only}
    1. 唐静, 陈铁宏. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(17):2243‐4.
Tao 2008 {published data only}
    1. Tao S‐W, Chen Q, Yang C, Pan R‐D, Pan T‐W, Li L, et al. A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents [4种非典型抗精神病药物对精神分裂症患者脂代谢的影响]. Journal of the Youjiang Medical College for Nationalities 2008;6:927‐30.
Tong 2007 {published data only}
    1. Tong J, Yang Z. Control study of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(1):7‐10.
Tu 2009 {published data only}
    1. 涂国和, 胡有平, 周学儿. Aripiprazole (Booz Qing) and risperidone in the treatment of schizophrenia in the clinical control study] Google Translate [阿立哌唑(博思清)与利培酮治疗精神分裂症的临床对照研究]. Jiangxi Medical Journal [江西医药] 2009; Vol. 44, issue 8:799‐800.
Wang 2005 {published data only}
    1. Wang R, Liu Y, Ning Z. A controlled study of aripiprazole vs clozapine in the treatment of first‐episode schizophrenia. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2005;11(4):301‐2.
Wang 2006 {published data only}
    1. Wang G‐P, Xie R, Pei G‐X, Zhang Y‐L. Comparative study between aripiprazole and clozapine in the treatment of patients with schizophrenia [阿立哌唑的临床应用（一）——阿立哌唑与氯氮平治疗精神分裂症对照研究]. Journal of Clinical Psychiatry 2006;16(1):44‐5.
Wang 2006a {published data only}
    1. Wang Y, Sun F, Zhang Z. Observation of therapeutic effect of aripiprazole in the treatment schizophrenic patients [阿立哌唑治疗精神分裂症的疗效观察]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(4):427‐8.
Wang 2006b {published data only}
    1. Wang G‐P. Effect of aripiprazole on quality of life of schizophrenic patients [阿立哌唑对精神分裂症患者生活质量的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2006; Vol. 16, issue 6:360‐1.
Wang 2006c {published data only}
    1. Wang H, Wang Y, Lu L. A comparative study between aripiprazole and risperidone in the treatment of chronic schizophrenia [阿立哌唑与利培酮治疗慢性精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(6):650‐1.
Wang 2006d {published data only}
    1. Wang D, Li Y, Feng Y. A controlled study of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2006;12(4):245‐6.
Wang 2007 {published data only}
    1. Wang D. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(17):751.
Wang 2007a {published data only}
    1. Wang L‐Z, Weng J‐Z, Zhuo Z‐M. Comparative study on aripiprazole and risperidone in treatment of female schizophrenia [阿立哌唑与利培酮治疗女性精神分裂症对照研究]. 西部医学 2007; Vol. 19, issue 1:42‐3.
Wang 2007d {published data only}
    1. 王学滨, 刘宏. A force of aripiprazole and risperidone in the treatment of schizophrenia [阿力哌唑与利培酮治疗精神分裂症对照研究]. 中外健康文摘 [医药学刊] 2007;4(11):44.
Wang 2007e {published data only}
    1. 王国富. Aripiprazole in the treatment of schizophrenia clinical observation [阿立哌唑治疗精神分裂症临床观察]. Journal of the Changzhi Medical College 2007;21(2):110‐1.
Wang 2008 {published data only}
    1. Wang Y‐C, Wang J‐L, Yuan J‐M. A controlled study of effect on schizophrenia serum prolactin level aripiprazole [阿立哌唑对精神分裂症患者血清催乳素的影响]. 中国实用医药 2008;3(21):38‐9.
Wang 2008c {published data only}
    1. 王天龙, 程平, 陈红光, 唐鹏, 周桂明. Ziprasidone treatment of schizophrenia with predominantly negative symptoms [齐拉西酮治疗以阴性症状为主精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(3):206‐7.
Wang 2009 {published data only}
    1. 王茂萍. New antipsychotic drug aripiprazole on glucose metabolism and glycosylated hemoglobin [新型抗精神病药物阿立哌唑对糖代谢影响及与糖化血红蛋白的关系]. Hebei Medical Journal 2009; Vol. 31, issue 14:1752‐3.
Wei 2006 {published data only}
    1. Wei S‐Z, Tang Q‐S, Xu Z‐N, Ruan X‐J, Lu B. A randomized, double blind, double dummy parallel controlled study in the female first‐episode schizophrenia treated with aripiprazole and quetiapine [阿立哌唑与奎硫平治疗女性首发精神分裂症的随机、双盲、双模拟平行对照研究]. Chinese Journal of Nervous and Mental Diseases 2006;32(6):511‐7.
    1. 韩树华. Aripiprazole and quetiapine in the treatment of schizophrenia control study of women] Google Translate [阿立哌唑与奎硫平治疗女性首发精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010; Vol. 22, issue 5:511‐6.
Wei 2007 {published data only}
    1. 魏月玲, 韩鹏, 魏春香. Control study of aripiprazole and clozapine in schizophrenia affect the quality of life in patients with [阿立哌唑与氯氮平对精神分裂症患者生活质量影响的对照研究]. Sichuan Mental Health [四川精神卫生] 2007;20(2):80‐2.
Wei 2009 {published data only}
    1. 魏丽霞, 刘传军, 杨波, 崔宏维. Olanzapine A Leekpai azole treatment of schizophrenia [奥氮平与阿立派唑治疗精神分裂症对照研究]. 中国实用医药 2009;4(16):166‐7.
Wen 2009 {published data only}
    1. 文启琴, 黄远光, 马静山. aripiprazole and risperidone in the treatment of female controlled study of schizophrenia] Google Translate [阿立哌唑与利培酮治疗女性首发精神分裂症的对照观察]. Guangdong Medical Journal [广东医学] 2009;30(6):987‐8.
Wen 2009a {published data only}
    1. 文家松, 夏南, 胡晓丽. Comparison of aripiprazole and risperidone in the treatment of female schizophrenia [阿立哌唑与利培酮治疗女性精神分裂症的对照研究]. Journal of the North Sichuan Medical College 2009;24(4):342‐3.
Wlodzmierz 2006 {published data only}
    1. Sanchez R, Kostic D, Stock E, Torbeyns AF, Kerselaers W, Nyilas M, et al. Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: A 52‐week open‐label extension study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006.
    1. Wlodzimierz CK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long‐term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52‐week, open‐label comparison with olanzapine. Psychopharmacology 2006;189(2):259‐66. - PubMed
Wolf 2007 {published data only}
    1. Beuzen J‐N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al. Broad effectiveness trial with aripiprazole in Europe Eu‐Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2‐6; Munich, Germany. 2005.
    1. Beuzen J‐N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, et al. Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005.
    1. Beuzen J‐N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al. Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006.
    1. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al. A prospective, multi centre, open‐label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with aripiprazole in Europe (EU‐BETA). Current Medical Research and Opinion 2007;23(10):2313‐23. [MEDLINE: ] - PubMed
Wu 2008 {published data only}
    1. Wu S, Liu H‐Y, Huo X‐P. A comparative study of aripiprazole and risperidone in the treamtment of senile schizophrenia [阿立哌唑与利培酮治疗老年期精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(15):1723‐4.
Xiao 2007 {published data only}
    1. Xiao G‐C, Wang D‐P, Huang G‐P. Comparative study on the clinical effect and the life quality of schizophrenic patients treated with aripiprazol and clozepine [阿立哌唑与氯氮平治疗精神分裂症患者疗效及生活质量的对照研究]. 中国医疗前沿 2007; Vol. 1, issue 2:28‐9.
Xie 2008 {published data only}
    1. 谢新年, 舒人九, 钦桃桃. Aripiprazole and risperidone in the treatment of male schizophrenia efficacy and sexual function [阿立哌唑及利培酮治疗男性精神分裂症的疗效及对性功能的影响]. Hunan Medical Journal 2008; Vol. 25, issue 6:1111‐3.
Xie 2010 {published data only}
    1. 谢根生, 赵新蕾, 钱国平, 吴玉红, 胡庆芬. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症对照研究]. 中国预防医学杂志 2010; Vol. 11, issue 2:190‐2.
Xu 2007 {published data only}
    1. 徐美勤. Aripiprazole and clozapine treatment of schizophrenia analysis [阿立哌唑与氯氮平治疗精神分裂症对照分析]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007; Vol. 13, issue 6:548‐9.
Xu 2010 {published data only}
    1. 徐筠, 李朝, 王慧芳, 李华芳. Aripiprazole and risperidone in the treatment of schizophrenia randomized double‐blind controlled study] Google Translate [阿立哌唑与利培酮治疗精神分裂症随机双盲对照研究 []. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2010; Vol. 20, issue 1:35‐7.
Yan 2007 {published data only}
    1. 阎美英, 刘方莹, 仇爱玫. Aripiprazole impact on the quality of life of patients with schizophrenia [阿立哌唑对精神分裂症病人生活质量影响的研究]. 家庭护士 2007;5(11C):15‐6.
Yan 2008 {published data only}
    1. 闫凤娟, 刘雪峰. Aripiprazole and risperidone in the treatment of children with schizophrenia [阿立哌唑与利培酮治疗儿童精神分裂症对照研究]. 中国医学文摘 [儿科学] 2008;27(6):465‐6.
Yan 2008a {published data only}
    1. 闫宝昌. Aripiprazole and clozapine treatment of refractory schizophrenia [阿立哌唑与氯氮平治疗难治性精神分裂症的对照观察]. Chinese Journal of Misdiagnostics [中国误诊学杂志] 2008;8(18):4304‐5.
Yan 2010 {published data only}
    1. 晏桂萍, 朱志雾, 丁寒春, 杨春霓. Aripiprazole and risperidone in patients with first‐episode schizophrenia comparative efficacy and safety study] Google Translate [阿立哌唑和利培酮对首发分裂症患者疗效及安全性的对照研究]. 中国当代医药 2010; Vol. 17, issue 22:37‐9.
Yang 2006 {published data only}
    1. Yang L, Yang K, Yao X. A comparative between aripiprazole and clozapine in the treatment of schizophrenia [阿立哌唑与氯氮平治疗精神分裂症的疗效比较]. Sichuan Mental Health [四川精神卫生] 2006;19(2):92‐4.
Yang 2007 {published data only}
    1. Yang T‐R, Song B‐L, Yuan C‐Q. Control study of aripiprazole and clozapine in treatment of patients with schizophrenia [阿立哌唑与氯氮平治疗精神分裂症患者的疗效比较]. 西部医学 2007; Vol. 19, issue 2:234‐5.
Yang 2008 {published data only}
    1. Yang J, Zhu G‐H, Xie J. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia [齐拉西酮与阿立哌唑治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(23):2760‐1.
Yang 2008a {published data only}
    1. Yang X, Deng H, Wen W. Study of aripiprazole in treatment of first‐episode schizophrenia [阿立哌唑治疗首发精神分裂症30例]. China Pharmaceuticals [中國藥業] 2008;17(5):52‐3.
Yang 2008b {published data only}
    1. a杨荣. Aripiprazole in the treatment of female schizophrenia [阿立哌唑治疗女性精神分裂症对照研究]. 中国现代医生 2008;46(13):100‐1.
Yang 2009 {published data only}
    1. 杨春强, 李宝珠. Aripiprazole and olanzapine on body weight, blood glucose control study effects of] Google Translate [阿立哌唑与奥氮平对体质量、血糖影响的对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009; Vol. 19, issue 5:339‐40.
Ye 2005 {published data only}
    1. Ye X‐R, Xia X‐L. A comparative study between aripiprazole and risperidone in treatment of first‐onset schizophrenia. Medical Journal of National Defending Forces in Southwest China 2005;15(6):616‐8.
Ye 2005a {published data only}
    1. Ye C‐W, Pan D‐J, Ni X‐J, Pan J‐L, Zhu G‐D. Controlled study between aripiprazole and olanzapine on schizophrenia [阿立哌唑与奥氮平治疗精神分裂症的对照研究]. Modern Research of Integrated Chinese and Western Medicine [现代中西医结合杂志] 2005; Vol. 14, issue 24:3199‐200.
Yi 2007 {published data only}
    1. Yi F, Zhen D L‐L, Wang J‐L, Xu L‐F, Yang G‐P. A comparative study of blood2glucose metabolism between aripiprazole and clozapine in treatment of patientswith schizophrenia [阿立哌唑与氯氮平对精神分裂症患者血糖代谢的影响]. Journal of Clinical Psychological Medicine [临床精神医学杂志] 2007; Vol. 17, issue 4:253.
Yu 2006 {published data only}
    1. Yu C‐X, Ji D‐C, Yuan H. The study of clinical efficacy of aripiprazole in the treatment for refractory schizophrenia [阿立哌唑治疗难治性精神分裂症的疗效观察]. Shandong Jingshen Yixue 2006;19(4):263‐5.
Yu 2006a {published data only}
    1. Yu L. Effects of aripiprazole vs. clozapine on body weight and blood sugar levels of schizophrenics [阿立哌唑与氯氮平对精神分裂症患者体重及血糖的影响]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2006;12(6):422‐3.
Yu 2007 {published data only}
    1. Yu L, Li B. A control study of aripirazole and clozapine in the treatment of first‐episode schizophrenia [阿立哌唑与氯氮平治疗首发精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(2):115‐6.
Yu 2008 {published data only}
    1. 于永涛. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(19):2267, 2269.
Yu 2009 {published data only}
    1. 余瑞高. Aripiprazole and clozapine in the treatment of chronic schizophrenia] Google Translate [阿立哌唑与氯氮平治疗慢性精神分裂症的对照研究]. Medical Journal of Liaoning 2009;23(4):211‐2.
Yu ZG 2007 {published data only}
    1. 余志刚, 刘金鹏/继龙, 刘军. Controlled clinical studies of aripiprazole and clozapine in the treatment of schizophrenia [阿立哌唑与氯氮平治疗精神分裂症临床对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(12):1066‐7.
Zhang 2006 {published data only}
    1. Zhang Y, Li G, An B. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与维思通治疗精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006; Vol. 14, issue 6:635‐6.
Zhang 2006a {published data only}
    1. Zhang Y, Gao G, Zhang Q. A comparative study of aripiprazole versus olanzapine in the treatment of chronic schizophrenia [阿立哌唑与奥氮平治疗慢性精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(4):429‐30.
Zhang 2007 {published data only}
    1. Zhang R‐X, Cai Y‐F, Zhao L‐G. A comparative study of EKG changed by aripiprazole and clozapine in the treatment of schizophrenia [阿立哌唑与氯氮平对精神分裂症病人心电图影响的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(12):1016, 1018.
Zhang 2007a {published data only}
    1. Zhang Y, Zhang H, Gu W. A control study of aripiprazole in the treatment of childhood schizophrenia [阿立哌唑治疗儿童精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2007;13(2):122‐4.
Zhang 2007b {published data only}
    1. Zhang Z‐L, Xiao X‐Y, Nie B. Clinical control study of aripiprazole and risperidone in the treatment of first‐ episode schizophrenia [阿立哌唑与利培酮治疗首发精神分裂症对照研究]. Modern Medicine and Health [现代医药卫生] 2007;23(4):494‐5.
Zhang 2008 {published data only}
    1. Zhang J. Comparative investigation on aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照分析]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報] 2008;29(13):1542‐3.
Zhang 2008a {published data only}
    1. 张振东. Controlled clinical observation of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症临床对照观察]. Guangzhou Medical Journal 2008;39(3):52‐3.
Zhang 2008b {published data only}
    1. 张胜利, 盛民生, 李永强, 李振宇. Comparison of the efficacy of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的疗效比较]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(20):2386, 2435.
Zhang 2009 {published data only}
    1. 张艳琦, 于振东. Aripiprazole and clozapine in treatment refractory schizophrenia comparative observation] Google Translate [阿立哌唑与氯氮平治疗难治性精神分裂症疗效比较观察]. People's Military Surgeon [人民军医] 2009; Vol. 52, issue 12:822‐3.
Zhang 2009a {published data only}
    1. 张东卫, 甘景梨, 高存友, 段惠峰. Aripiprazole and risperidone on glucose and lipid] Google Translate [阿立哌唑与利培酮对血糖、血脂的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;19(5):343‐5.
Zhang 2009b {published data only}
    1. 张灵娥, 张金光, 张珍. Aripiprazole and risperidone in the treatment of schizophrenia] Google Translate [阿立哌唑与利培酮治疗精神分裂症对照研究]. Journal of Baotou Medical College [包頭醫學院學報] 2009;25(6):41‐2.
Zhang 2010 {published data only}
    1. 张启林, 翟江. Aripiprazole and clozapine in treatment refractory schizophrenia] Google Translate [阿立哌唑与氯氮平治疗难治性精神分裂症的对照研究]. West China Medical Journal [华西医学] 2010; Vol. 25, issue 6:1033‐5.
Zhang 2010a {published data only}
    1. 张玉清, 王彩萍. Aripiprazole and risperidone in the treatment of schizophrenia comparative analysis of 100 cases] Google Translate [阿立哌唑与利培酮治疗精神分裂症100例的对比分析]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease [实用心脑肺血管病杂志] 2010;18(6):762.
Zhao 2006 {published data only}
    1. Zhao L, Wang M, Wang B. A controlled study of aripiprazole versus quetiapine in the treatment of first‐episode schizophrenia [阿立哌唑与奎的平治疗首发精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(6):663‐4.
Zhao 2007 {published data only}
    1. Zhao S‐M, Du B, Li K‐Q. A comparative study of aripiprazole versus risperdal in patients with schizophrenia [奥派与利培酮治疗精神分裂症临床对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(5):195‐7.
Zhi 2005 {published data only}
    1. Zhi S‐L. Comparison study of aripiprazole and risperidone on schizophrenia. Modern Jorunal of Integrated Traditional Chinese and Western Medicine 2005;14(21):2787‐8.
Zhou 2007 {published data only}
    1. 周平, 刘联琦. Aripiprazole and clozapine treatment of schizophrenia [阿立哌唑与氯氮平治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007; Vol. 17, issue 2:126‐7.
Zhou 2007a {published data only}
    1. 周伟东. Aripiprazole and risperidone in the treatment of schizophrenia control observation [阿立哌唑与利培酮治疗首发精神分裂症的对照观察]. Journal of the Youjiang Medical College for Nationalities 2007;29(3):384‐5.
Zhou 2007b {published data only}
    1. 周雨林. Aripiprazole impact on the quality of life in patients with schizophrenia [阿立哌唑对精神分裂症患者生活质量的影响]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(5):354, 356.
Zhou 2008 {published data only}
    1. 周勇, 陈雪芳, 林勇, 刘勇. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. 精神医学杂志 2008;21(2):139‐40.
Zhu 2005 {published data only}
    1. Zhu P‐J, Cheng Z‐E, Zhang J, Zhu P‐L, Zhan X‐M. Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia. Chinese Journal of Clinical Pharmacology and Therapeutics 2005;10(10):1194‐7.
    1. Zhu P‐L, Zhu P‐J, Chen Z‐E, Zhang J, Zhan X‐M, Li Q‐Z. Treatment of 40 cases of schizophrenia with aripiprazole [阿立哌唑治疗精神分裂症40例]. Herald of Medicine [医药导报] [醫藥導報] 2006;25(6):536‐8.
Zhu 2008 {published data only}
    1. 朱满连, 潘大津, 卢舜飞. A Leekpai azole quetiapine controlled study for the treatment of schizophrenia [阿立派唑与喹硫平治疗精神分裂症的对照研究]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine [实用中西医结合临床] 2008;8(1):9‐10.
Zhu 2010 {published data only}
    1. 朱逸溪. Risperidone and olanzapine and aripiprazole on cognitive function in chronic schizophrenia] Google Translate [奥氮平和利培酮及阿立哌唑对慢性精神分裂症认知功能的影响]. 中华临床医师杂志(电子版) 2010; Vol. 4, issue 9:1709‐12.
Zimbroff 2007 {published data only}
    1. Pfizer. A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov 2008.
    1. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double‐blind, 4‐week study. International Clinical Psychopharmacology 2007;22(6):363‐70. [MEDLINE: ] - PubMed
Zou 2006 {published data only}
    1. Zou K‐Q, Jiang Q‐L, Wang D. Comparative study on effects of aripiprazole and clozapine [阿立哌唑与氯氮平的临床对照研究]. 中华现代内科学杂志 2006; Vol. 3, issue 1:17‐9.

References to studies excluded from this review

Ai 2008 {published data only}
    1. Ai C‐Q, Chen S‐M. Comparison study in the treatment of schizophrenia between aripiprazole and clozapine [阿立哌唑与氯氮平治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(1):53‐4.
Allen 2007 {published data only}
    1. Allen M, Talbott S, Eudicone J, McQuade R, Pikalov A. Similar rates of agitation, anxiety and insomnia in sedating and non‐sedating antipsychotics: evaluating clinical trial results with aripiprazole, haloperidol and olanzapine. Schizophrenia Bulletin 2007;33(2):418.
Anon 2008 {published data only}
    1. Anon. Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia. http://www.clinicaltrials.gov 2008.
Bao 2007 {published data only}
    1. Bao L‐Y, Wang K‐M. The effectiveness of aripiprazole combined with clonazepam treated with agitation in schizophrenia [阿 立 哌 唑 合 用 氯 硝 西 泮 治 疗 精 神 分 裂 症 兴 奋 症 状 疗 效 分 析]. Medical Journal of Chinese People's Health 2007;19(3):198‐200.
Bergman 2007 {published data only}
    1. Bergman M, Friedman JI, Stawarz K, Bowman A, Siever L, Cavagna M, et al. A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia. http://www.clinicaltrials.gov 2007.
Bristol‐Myers 2006 {published data only}
    1. Bristol‐Myers Squibb, Otsuka America Pharmaceutical. A multicenter, randomized, double‐blind, placebo‐controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy. http://www.clinicaltrials.gov 2006.
Carson 2000 {published data only}
    1. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology 2000;10(Suppl 3):S309.
Casey 2003 {published data only}
    1. Casey D, L'Italien G, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17– 22; San Francisco, California, USA. 2003.
Chen 2005 {published data only}
    1. Chen J‐D, Zhao J‐P, Li L‐H, Guo X‐F, Zhai J‐G, Wang C‐Y, et al. A multi centre, randomised and double‐blind controlled trial of aripiprazole in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2005;11:845‐8.
Chen 2007 {published data only}
    1. Chen J, Zhou Y, Zha X‐Y. A comparative study of aripiprazole and clozapine in the treatment of first‐episode schizophrenia [阿立哌唑与氯氮平治疗首发精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2007;20(2):97‐8.
Chen 2008 {published data only}
    1. Chen Q‐S, Li Y‐H, Qu L‐J. A comparative study of aripiprazole and risperidone in the treatment of the first episode schizophrenia [阿立哌唑和利培酮治疗首发精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(5):394‐5.
Chen LJ 2010 {published data only}
    1. 陈莉晶. Aripiprazole and risperidone in the treatment of schizophrenia compared] Google Translate [阿立哌唑与利培酮治疗精神分裂症的对比分析]. 当代医学 2010;16(4):140‐1.
Chen YH 2010 {published data only}
    1. 陈永红. Aripiprazole and risperidone in the treatment of female schizophrenia] Google Translate [阿立哌唑与利培酮治疗女性精神分裂症的对照研究]. Shanxi Clinical Medicine 2010;19(9B):1232‐4.
Colombo 2008 {published data only}
    1. Colombo GL, Caruggi M, Matteo S, Rossi A. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment 2008;4(5):967‐76. - PMC - PubMed
Cornblatt 2002 {published data only}
    1. Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research 2002;53(3 Suppl 1):27.
Fawzi 2009 {published data only}
    1. Fawzi M, Fawzi M Jr. Aripiprazole, olanzapine and olanzapine‐clomipramine combination in schizophrenia with obsessive‐compulsive symptoms. World Psychiatry 2009;8(Suppl 1):NRS5.4.
Fleischhacker 2008a {published data only}
    1. Fleischhacker W, Heikkinen ME, Olie JP, Dewaele P, McQuade R, Hennicken D, et al. Long‐term effect on weight of aripiprazole‐clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology 2008;18:S447.
    1. Markovic O. A multicenter, comparative, randomized, double‐blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. http://www.clinicaltrials.gov 2006.
Geng 2009 {published data only}
    1. 耿寒松, 刘荣芹, 边辛丑, 苏秀茹, 崔春青, 蒋龙, et al. Comparative study of the effects of ariplprazole and risoeridone on the therapeutic effect and patients’weight in patients with schizophrenia [阿立哌唑与利培酮对精神分裂症疗效与体重的对照研究]. Hebei Medical Journal 2009; Vol. 31, issue 4:407‐9.
Guan 2007 {published data only}
    1. Guan H‐Y, Wang K‐Q, Jiang L, Geng H‐S, Li Q‐X, Liu Z‐R, et al. A controlled study of efficacy between aripiprazole and risperidone in the treatment of patients with [阿立哌唑与利培酮治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007;17(4):241‐3.
Han HF 2010 {published data only}
    1. 韩惠芬. Second generation of psychiatric drugs 3 cost of the treatment of schizophrenia] Google Translate [3种二代精神病药治疗精神分裂症的成本分析]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報] 2010; Vol. 31, issue 9:1379‐80.
Hatta 2009 {published data only}
    1. Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research 2009;113(1):49‐55. - PubMed
Henderson 2009 {published data only}
    1. Henderson DC, Fan X, Copeland PM, Borba CP, Freudenreich O, Evins AE, et al. Aripiprazole added to overweight and obese olanzapine‐treated schizophrenia patients. Journal of Clinical Psychopharmacology 2009;29(2):165‐9. - PMC - PubMed
    1. Roussel JJ, Machon DA, Henderson DC. A placebo‐controlled, cross‐over trial of aripiprazole added to obese olanzapine‐treated patients with schizophrenia. http://www.clinicaltrials.gov 2006.
Huang 2008 {published data only}
    1. Huang X, Du W, Xue S, Tong Z, Jiang Z. Clinical efficacy of aripiprazole and risperidone in treating schizophrenia and their influence [阿立哌唑与利培酮治疗精神分裂症的临床疗效及对血清催乳素的影响]. 药物不良反应杂志 2008;10(2):77‐80.
Janssen 2005 {published data only}
    1. Janssen F. A comparative, randomized, open‐label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out‐patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone. http://www.clinicaltrials.gov 2005.
Jiang 2007 {published data only}
    1. Jiang Y‐H, Shen Z‐X. A comparison between the therapeutic effects of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的疗效比较]. Herald of Medicine [医药导报] [醫藥導報] 2007;26(10):1147‐8.
Ju 2009 {published data only}
    1. 鞠康, 费玥, 季卫东, 高运兰. Comparative analysis of aripiprazole and risperidone in the treatment of schizophrenia negative emotions [阿立哌唑与利培酮治疗精神分裂症负性情绪的比较分析]. Sichuan Mental Health [四川精神卫生] 2009;22(1):39‐40.
Kim 2006 {published data only}
    1. Kim YS. A double‐blind randomized placebo controlled study of aripiprazole augmentation for clozapine‐treated patients with refractory schizophrenia. http://www.clinicaltrials.gov 2006. - PubMed
Kim 2009 {published data only}
    1. Kim C‐Y. A multi‐center, randomized, open, treatment‐switching study from orally administered antipsychotic monotherapy in the treatment of chronic schizophrenic and schizoaffective patients. http://www.clinicaltrials.gov 2006.
    1. Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, et al. A 12‐week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 2009;24(4):181‐8. [MEDLINE: ] - PubMed
Lan 2008 {published data only}
    1. Lan T, Chiu H, Hu T, Huang H, Wu B, Tuan Y. Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia. European Neuropsychopharmacology 2008;18:S440.
Li 2007e {published data only}
    1. Li A‐F, Yao J‐X, Liao X‐H. A controlled study of domestic aripiprazole and clozapine in the treatment of refractory schizophrenia [国产阿立哌唑与氯氮平治疗难治性精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(5):165‐7.
Li 2007f {published data only}
    1. Li D, Yu L‐B, Zha Z‐Q. A comparative study on quality of life of female schizophrenics treated with aripiprazole [阿立哌唑对女性精神分裂症患者生活质量的影响]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(5):170‐2.
Liang 2005 {published data only}
    1. Liang S. A multi‐center, randomized, double‐blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. http://www.clinicaltrials.gov 2005.
Li C 2010 {published data only}
    1. 李超, 李慧娥, 刘彩秀. Aripiprazole and clozapine in the treatment of schizophrenia were] Google Translate [阿立哌唑和氯氮平治疗精神分裂症临床对照分析]. Acta Medicinae Sinica [华夏医学] 2010; Vol. 23, issue 4:391‐3.
Liemburg 2011 {published data only}
    1. Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well‐being. Pharmacopsychiatry 2011;44(3):109‐13. - PubMed
Lin 2006 {published data only}
    1. Lin C. A controlIed study of aripiprazole and risperidone in treatment of first‐episode schizophrenia [博思清与利培酮治疗首发精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006; Vol. 14, issue 6:660‐1.
Lin Y 2009 {published data only}
    1. 林云, 汪孝魁, 温达民, 黄航. Control study of aripiprazole and clozapine in the treatment of the negative symptoms of schizophrenia [阿立哌唑与氯氮平治疗精神分裂症阴性症状的对照研究]. Sichuan Mental Health [四川精神卫生] 2009; Vol. 22, issue 1:38‐9.
Liu 2007a {published data only}
    1. Liu G, Cai Y. A comparison study on the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的临床对照研究]. Modern Hospital 2007;7(8):36‐7.
Liu 2007b {published data only}
    1. Liu L, Xinag H. Compared effect and safety analysis of aripiprazole in late‐onset schizophrenia [阿立哌唑治疗晚发性精神分裂症的疗效对照分析]. Sichuan Mental Health [四川精神卫生] 2007;20(3):142‐4.
Liu XH 2009 {published data only}
    1. 刘晓红, 李卫军, 季磊. Clinical comparison of aripiprazole and risperidone in the treatment of female schizophrenia [阿立哌唑与利培酮治疗女性精神分裂症的临床比较]. Sichuan Mental Health [四川精神卫生] 2009; Vol. 22, issue 2:115‐6.
Lu 2008 {published data only}
    1. 卢艳春, 李扬. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008; Vol. 20, issue 23:2804.
Lv 2006 {published data only}
    1. Lv X‐M, Jia Z‐L, Liu C‐J. Effect of aripiprazole on body weight and blood glucose in the treatment of first‐episode schizophrenia [阿立哌唑对首发精神分裂症体重及血糖的影响]. Shandong Archives of Psychiatry [山东精神医学] 2006;19(3):181‐2.
Ma 2007 {published data only}
    1. Ma Q, Lian H‐T, Li L‐X. A study of aripiprazole combined with clozapine in refractory schizophrenia [阿 立 哌 唑 合 并 氯 氮 平 治 疗 难 治 性 精 神 分 裂 症]. Medical Journal of Chinese People's Health [中 国 民 康 医 学 ] 2007;19(12):1046, 1048.
Ma 2009b {published data only}
    1. 马闯胜, 马玲, 张淑芳. Comparative study on aripiprazole and risperidone in the treatment of female patients with schizophrenics [阿立哌唑与利培酮治疗女性精神分裂症的对比分析]. 实用药物与临床 2009;12(2):77‐9.
Medori 2008 {published data only}
    1. Medori R, Wapenaar R, Arce R, Rouillon F, Gaebel W, Cordes J, et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008.
Millar 2008 {published data only}
    1. Millar H, Felter C, Landsberg W. The effects of aripiprazole in combination with clozapine: patient functioning results from a double‐blind, 16‐week study in patients with schizophrenia (CN138‐170). Journal of Psychopharmacology 2008;22(5):A17.
Mortimer 2004 {published data only}
    1. Mortimer AMP. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence‐Based Mental Health 2004;7(2):41. [MEDLINE: ] - PubMed
Mossner 2009 {published data only}
    1. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics 2009;19(1):91‐4. [MEDLINE: ] - PubMed
Namey 2006 {published data only}
    1. Namey LB, Henderson DC. Aripiprazole for clozapine associated medical morbidity. http://www.clinicaltrials.gov 2006.
Newcomer 2006 {published data only}
    1. Newcomer JW, L'Italien G, Vester‐Blokland, McQuade RD, Carson WH, Marcus RN. Improvement of non‐hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006.
Newcomer 2008 {published data only}
    1. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester‐Blokland E, et al. Changes in non‐high‐density lipoprotein cholesterol levels and triglyceride/high‐density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2‐3):300‐7. - PMC - PubMed
Newcomer 2008c {published data only}
    1. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester‐Blokland E, et al. Changes in non‐high‐density lipoprotein cholesterol levels and triglyceride/high‐density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2‐3):300‐7. - PMC - PubMed
Pae 2009a {published data only}
    1. Pae CU, Serretti A, Chiesa A, Mandelli L, Lee C, Kim J, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology 2009;19(8):562‐70. - PubMed
Ray 2004 {published data only}
    1. Ray S, Corey‐Lisle PK, Cislo PR, L'Italien G, Weiden P. An economic evaluation of aripiprazole compared to olanzapine based on metabolic side‐effect profile. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S279.
Remington 2009 {published data only}
    1. Remington G. Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence‐Based Mental Health 2009;12(2):51. - PubMed
Schreiner 2009 {published data only}
    1. Schreiner A, Arce R, Eding E, Marques‐Teixeira J, Milanova V, Rancans E, et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28‐Jul 2; Paris, France. 2009. - PubMed
Shen 2006 {published data only}
    1. Shen J‐Q, Shi J‐F. A controlled study on aripiprazole and risperidone in the treatment of schizophrenic patients [阿立派唑与利培酮治疗门诊首发精神分裂症的临床研究]. Chinese Journal of Modern Applied Pharmacy 2006;23(7):714‐6.
Shim 2006 {published data only}
    1. Shim JC, Kelly DL, Jung DU, Seo YS, Kim YH, Conley RR. Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia. European Neuropsychopharmacology 2006;16(Suppl 4):S405. - PubMed
Sun 2006a {published data only}
    1. Sun F, Dong R, Wang Y. A randomized control study aripiprazole in the treatment of first‐episode schizophrenia [阿立哌唑治疗首发精神分裂症的随机对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(6):642‐3.
Sun P 2009 {published data only}
    1. 孙鹏, 岳英, 张正怡, 张毅蓉, 徐一峰. Quetiapine, aripiprazole treatment efficacy in patients with acute schizophrenia] Google Translate [喹硫平、阿立哌唑治疗急性期精神分裂症患者疗效观察]. Shandong Archives of Psychiatry [山东精神医学] 2009;22(5):381‐2.
Takeuchi 2008 {published data only}
    1. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al. A randomized, open‐label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add‐on, wait, and tapering of previous antipsychotics versus add‐on and simultaneous tapering. Journal of Clinical Psychopharmacology 2008;28(5):540‐3. - PubMed
Talbott 2007 {published data only}
    1. Talbott S, Buckley P, Eudicone J, McQuade R, Van‐Tran Q. Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine‐analyses of the first 12 weeks of three double‐blind, long‐term trials. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1; Colorado Springs, Colorado, USA 2007.
Taylor 2007 {published data only}
    1. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence‐Based Mental Health 2007;10(3):76. [MEDLINE: ] - PubMed
Wang 2006e {published data only}
    1. Wang X‐Q, Zhou H‐X, Zhang Y‐L, Wang H‐Y, Gao T‐X, Xie P‐L. Clinical study of aripiprazole and risperidone in treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症临床研究]. Journal of Clinical Psychiatry 2006; Vol. 16, issue 2:108‐9.
Wang 2007b {published data only}
    1. Wang K‐Q, Guan H‐Y, Jiang L, Geng H‐S, Li Q‐X, Liu Z‐R, et al. A controlled study of effect on serum prolactin level between aripiprazole and risperidone [阿立哌唑与利培酮对血清催乳素水平的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007; Vol. 17, issue 3:154‐6.
Wang 2007c {published data only}
    1. Wang Y, Chen T. Non ‐ classical antipsychotic drugs for schizophrenia: cost ‐ minimization analysis on 3 schemes [3种非经典抗精神病药治疗精神分裂症的最小成本分析]. China Pharmacy [中國藥房] 2007;18(32):2487‐8.
Watts 2006a {published data only}
    1. Watts KL, Wilson H, Tang T. Estimating and reducing the cardiovascular risk of patients with schizophrenia drugs from lipid measures and ischemic electrocardiographic changes. http://www.clinicaltrials.gov 2006.
Xu 2008 {published data only}
    1. Xu M, Zheng G‐X. Comparative study of aripiprazole and risperidone for schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Jilin Medical Journal 2008;29(19):1629‐30.
Yang 2007a {published data only}
    1. Yang W, Liu X‐Q, Li X‐W. A ramdomized controlled clinical study of aripiprazole in the treatment of childhood schizophrenia [阿立呱唑治疗儿童精神分裂症多中心随机对照研究]. Hunan Medical Journal 2007;24(6):942‐4.
Yang 2007b {published data only}
    1. Yang S, Gao S, Wu X. A control study of aripiprazole vs. clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(1):15‐6.
Yu 2007a {published data only}
    1. Yu L. Comparative study of aripiprazole and risperidone in the treatment of female schizophrenias [阿立哌唑与利培酮治疗女性精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2007;15(10):948‐9.
Zeng 2006 {published data only}
    1. Zeng D‐Z, Chen K‐Q, Hu Z‐D. Influence of aripiprazole on life quality of the patients with schizophrenia [阿立哌唑对精神分裂症患者生活质量的影响]. Chinese Journal of Rehabilitation [中國康復] 2006;21(4):288.
Zhang 2006b {published data only}
    1. Zhang X‐L, Cui Y‐Z, Yang X‐S. Controlled study on aripiprazole in the treatment of schizophrenic patients who has response to clozapine [阿立哌唑替换氯氮平治疗精神分裂症的对照研究]. Medical Journal of Chinese Civil Administration 2006;18(9):753‐4.
Zhang F 2009 {published data only}
    1. 张帆, 熊昆武. Aripiprazole and quetiapine in the treatment control study of first‐episode schizophrenia] Google Translate [阿立哌唑与奎硫平治疗首发精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009;17(11):299‐300.
Zhang RK 2008 {published data only}
    1. 张仁凯, 付学凯, 王建利, 张春鹏. Aripiprazole and clozapine in the treatment of refractory schizophrenia [阿立哌唑与氯氮平治疗难治性精神分裂症的对照研究]. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao][齊齊哈爾醫學院學報] 2008;29(14):1703‐4.
Zhang XL 2007 {published data only}
    1. 张小聆, 黄献平, 卢友欢. Aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的对照研究]. Fujian Medical Journal [福建医药杂志] 2007;29(6):117‐8.
Zhao GW 2009 {published data only}
    1. 赵贵文. Aripiprazole and risperidone on serum prolactin levels] Google Translate [阿立哌唑与利培酮对血清催乳素水平的影响 []. Medical Journal of Liaoning 2009;23(4):221‐2.
Zhao JY 2009 {published data only}
    1. 赵晶媛, 郭素芹, 王新友. A control study on effect of domestic aripiprazole and clozapine in treatment of schizophrenia [国产阿立哌唑与氯氮平治疗精神分裂症的疗效及安全性对照研究]. Occupation and Health [职业与健康] 2009; Vol. 25, issue 6:666‐8.
Zhe 2007 {published data only}
    1. Zhe J, Shi X‐Y, Tan T‐C, Liu W‐X, Tao P‐Y, Wang J, et al. Comparative study of aripiprazole and risperidone in treatment of late onset schizophrenia [阿立哌唑与利培酮治疗晚发精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007; Vol. 17, issue 5:327‐8.
Zhi 2010 {published data only}
    1. 支胜利. aripiprazole and risperidone in the treatment of schizophrenia compared efficacy] Google Translate [阿立哌唑与利培酮治疗精神分裂症疗效对比 []. China Pharmaceuticals [中國藥業] 2010; Vol. 19, issue 1:52‐3.

References to studies awaiting assessment

Wang 2006f {published data only}
    1. Wang H, Wang Y, Lu L. A comparative study between aripiprazole and risperidone in the treatment of chronic schizophrenia [阿立哌唑与利培酮治疗慢性精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(6):650‐1.
Zhao 2006a {published data only}
    1. Zhao L, Wang M, Wang B. A controlled study of aripiprazole versus quetiapine in the treatment of first‐episode schizophrenia [阿立哌唑与奎的平治疗首发精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2006;14(6):663‐4.
Zheng XR 2008 {published data only}
    1. 郑孝荣. Aripiprazole in the treatment of schizophrenia, efficacy and safety analysis [阿立哌唑治疗精神分裂症的疗效与安全性分析]. Modern Practical Medicine 2008;20(6):457‐8.
陶建青, 2007 {published data only}
    1. 陶建青, 梁佳, 曾强, 康红. A controlled study on compliance of schizophrenia treated with aripiprazole and risperidone. Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20‐23; Shanghai. 2007:334.

References to ongoing studies

Bristol‐Myers 2009 {published data only}
    1. Bristol‐Myers Squibb. Metabolic abnormalities ‐ OPT. http://www.clinicaltrials.gov 2009.
Eli Lilly 2003 {published data only}
    1. Eli Lilly, Company. Study of olanzapine vs aripiprazole in the treatment of schizophrenia. Eli Lilly and Company Clinical Trial Registry 2003.
Essock 2002 {published data only}
    1. Essock SM, Covell NH, Carbuto M, Bielen K, Jabbour B, Saltz BL, et al. Effectiveness of switching antipsychotic medications. http://www.clinicaltrials.gov 2002.
Glorioso 2005 {published data only}
    1. Glorioso DK, Jeste DV. Metabolic effects of newer antipsychotics in older patients. http://www.clinicaltrials.gov 2005.
Hanssens 2007 {published data only}
    1. Hanssens L. A 16‐Week, multicenter, randomized, open‐label study to assess the effects of aripiprazole versus other atypical antipsychotics in the treatment of schizophrenic patients with metabolic syndrome. http://www.clinicaltrials.gov 2007.
Johnson 2006 {published data only}
    1. Johnson & Johnson Pharmaceutical Research & Development LLC. A 2‐year, prospective, blinded‐rater, open‐label, active‐controlled, multicenter, randomized study of long‐term efficacy and effectiveness comparing risperdal® consta® and abilify® (aripiprazole) in adults with schizophrenia. http://www.clinicaltrials.gov 2006.
Lehrer 2008 {published data only}
    1. Lehrer DS, Jewell M. Best event schizophrenia trial‐‐a randomized double‐blind trial of aripiprazole and risperidone in schizophrenia. http://www.clinicaltrials.gov 2008.
Lin 2009 {published data only}
    1. Lin C‐C. Identification and treatment response prediction of antipsychotic‐related metabolic syndrome. http://www.clinicaltrials.gov 2009.
Livingston 2007 {published data only}
    1. Livingston M, Stroup TS, McEvoy JP, Rojas I, Gamel N, Glick I, et al. Clinical management of metabolic problems in patients with schizophrenia. http://www.clinicaltrials.gov 2007.
McCormack 2006 {published data only}
    1. McCormack J, Robinson D, Tobias K, Petrides G, Robinson D, Sevy S, et al. Preventing morbidity in first episode schizophrenia, part II. http://www.clinicaltrials.gov 2006.
McEvoy 2007 {published data only}
    1. McEvoy JP. Metabolic signatures and biomarkers for aripiprazole. http://www.clinicaltrials.gov 2007.
Montoya 2006 {published data only}
    1. Montoya D, Blizard R, Buckley PF, Holman T, Kerr J, Miller DD, et al. Preventing relapse: oral antipsychotics compared to injectables: evaluating efficacy (PROACTIVE). http://www.clinicaltrials.gov 2006.
Schweiger 2005 {published data only}
    1. Schweiger J, Flavin K, Rosen B, Spies A, Newcomer JW, Haupt D. Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics. http://www.clinicaltrials.gov 2005.
Stroup 2007 {published data only}
    1. Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of antipsychotics for metabolic problems (CAMP): a NIMH schizophrenia trials network study. Clinical Schizophrenia and Related Psychoses 2007;1(1):69‐72.
Swartz 2008b {published data only}
    1. Swartz M, Stroup TS, McEvoy JP, Rojas IA. Comparison of optimal antipsychotic treatments for adults with schizophrenia. http://www.clinicaltrials.gov 2008.
Vontur 2005 {published data only}
    1. Vontur MG, Lopez J, Woolsey MD, Maples NL, Velligan DI. Do patients taking aripiprazole learn more in vocational skills training than patients taking olanzapine?. http://www.clinicaltrials.gov 2005.

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. - PMC - PubMed
APA 2004
    1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Psychiatric Publishing, Inc, 2004:1‐114.
Arnt 1998
    1. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63‐101. - PubMed
Barnes 1989
    1. Barnes TR. A rating scale for drug‐induced akathisia. British Journal of Psychiatry 1989;154:672‐6. - PubMed
Belgamwar 2011
    1. Belgamwar Ravindra B, El‐Sayeh Hany George G. Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2] - DOI - PMC - PubMed
Bhattacharjee 2008
    1. Bhattacharjee J, El‐Sayeh Hany George G. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3] - DOI - PMC - PubMed
Bland 1997
    1. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
BNF 2013
    1. British National Formulary (BNF). http://www.bnf.org/bnf/index.htm accessed June/July 2013.
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, et al. The problem of therapeutic efficacy indices.3. Comparison of the indices and their use. Therapie 1999;54(4):405‐11. - PubMed
Carpenter 1994
    1. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90. - PubMed
Chaichan 2008
    1. Chaichan W. Evaluation of the use of the positive and negative syndrome scale‐excited component as a criterion for administration of p. r. n. medication. Journal of Psychiatric Practice 2008;14(2):105‐13. [PUBMED: 18360196] - PubMed
Cipriani 2009
    1. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2] - DOI - PMC - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Proceeding of the 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Duggan 2005
    1. Duggan L, Dardennes R, El‐Dosoky A, Fenton M, Indran S, Rathbone J. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] - DOI - PMC - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder CSO. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;13:629‐34. - PMC - PubMed
EL‐Sayeh 2006
    1. El‐Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
FDA 2002
    1. U. S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm 2002 (accessed 18 August 2006).
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7‐10. - PubMed
Gaebel 2006
    1. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Guy 1976
    1. Guy U. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976.
Heinrichs 1984
    1. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10(3):388‐98. [PUBMED: 6474101] - PubMed
Heres 2006
    1. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185‐94. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org 2011.
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. - PubMed
Jelsma 2001
    1. Jelsma J, Mhundwa K, Weerdt W, Cock P, Chimera J, Chivaura V. The reliability of the Shona version of the EQ‐5D. Central African Journal of Medicine 2001;47(1):8‐13. [PUBMED: 11961858] - PubMed
Jones 2006
    1. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry 2006;63:1079‐6. - PubMed
Kane 1988
    1. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment‐resistant schizophrenia: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789‐96. - PubMed
Kane 1993
    1. Kane JM. Treatment programme and long‐term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585‐93. - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986.
Kolotkin 2002
    1. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life‐lite questionnaire (IWQOL‐lite) in a community sample. Quality of Life Research 2002;11(2):157‐71. [PUBMED: 12018739] - PubMed
Leucht 2005
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231‐8. - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797] - PubMed
Leucht 2007
    1. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183‐91. [PUBMED: 16905632] - PMC - PubMed
Leucht 2008
    1. Leucht S, Komossa K, Rummel‐Kluge C, Corves C, Hunger H, Schmid F, et al. A meta‐analysis of head‐to‐head comparisons of second‐generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166(2):152‐63. [DOI: 10.1176/appi.ajp.2008.08030368] - DOI - PubMed
Lieberman 2005
    1. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209‐23. - PubMed
Maayan 2011
    1. Maayan N, Soares‐Weiser K, Xia J, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD009005] - DOI - PMC - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Martindale 2013
    1. Martindale: the complete drug reference. http://www.medicinescomplete.com/mc/martindale/current/ accessed June/ July 2013.
Marvaha 2004
    1. Marvaha S, Johnson S. Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337‐49. - PubMed
McGahuey 2000
    1. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex & Marital Therapy 2000;26(1):25‐40. [PUBMED: 10693114] - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel‐ group randomized trials. JAMA 2001;285:1987‐1. - PubMed
Mukundan 2010
    1. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2; CD006629] - DOI - PMC - PubMed
Möller 2000
    1. Möller HJ. New assessment of atypical antipsychotics [Aktuelle bewertung neuer/atypischer neuroleptika]. Nervenarzt 2000;71:329‐44. - PubMed
O'Carroll 2000
    1. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL‐100 and the WHOQOL‐BREF in detecting change in quality of life following liver transplantation. Quality of Life Research 2000;9:121‐4. - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Pagadala 2009
    1. Pagadala B, Jayaram Mahesh B, Mitra L. Aripiprazole for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008074] - DOI
Rivas‐Vasquez 2003
    1. Rivas‐Vasquez RA. Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology 2003;34(1):108‐11.
Rust 1989
    1. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
Schünemann 2008
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83.
Simpson 1970
    1. Simpson EN, Angus JWF. A rating scale for extrapyramidal adverse effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11‐9. - PubMed
Tandon 2005
    1. Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, et al. Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research 2005;136(2‐3):211‐21. [PUBMED: 16115690] - PubMed
Tandon 2008
    1. Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia, "just the facts"What we know in 2008.2. Epidemiology and etiology. Schizophrenia Research 2008;102:1‐18. - PubMed
Thorpe 2009
    1. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic‐explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 2009;62(5):464‐75. [PUBMED: 19348971] - PubMed
Tsuang 1978
    1. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153‐5. - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92. - PubMed
Whitehead 2002
    1. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002305; PUBMED: 12076447] - DOI - PMC - PubMed
WHO 2001
    1. WHO. The World Health Report 2001 ‐ Mental Health: New Understanding, New Hope. Geneva: World Health Organization, 2001.
Xia 2007
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23‐27 October 2007. 2007.
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

References to other published versions of this review

Khanna 2013
    1. Khanna P, Komossa K, Rummel‐Kluge C, Hunger H, Schwarz S, El‐Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD006569.pub4] - DOI - PubMed
Komossa 2009
    1. Komossa K, Rummel‐Kluge C, Schmid F, Hunger H, Schwarz S, El‐Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3; PUBMED: 19821375] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources